Athira Pharma, Inc.ATHANASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.22% | +0.97% | +1.88% | +1.86% | +2.39% |
| Weighted Average Shares Diluted Growth | +1.22% | +0.97% | +1.88% | +1.86% | +2.39% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -100.00% | -100.00% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -53.30% | -63.32% | -67.40% | -68.05% | -65.18% |
| Book Value per Share Growth | -63.24% | -65.89% | -65.67% | -62.32% | -54.57% |
| Debt Growth | -21.41% | -23.22% | -25.43% | -27.72% | -30.59% |
| R&D Expense Growth | -34.12% | -60.43% | -79.51% | -83.29% | -85.59% |
| SG&A Expenses Growth | -3.42% | -11.00% | -18.87% | -38.20% | -46.53% |